Form 10-K for the fiscal year ended December 31, 2024
Please provide revised disclosure to be included in future filings to break out research and development expenses by clinical program or trial. For amounts that are not tracked by program, provide other quantitative or qualitative disclosure that provides more transparency as to the type of research and development expenses incurred (i.e.Rest of the question
by nature or type of expense) for each period presented which should reconcile to total research and development expense on the Statements of Operations. In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
The Company respectfully acknowledges the Staff’s comment and will revise its future filings to include the following disclosure to explain research and development expenses, starting with the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2025. The following disclosure is based on the Company’s second quarter research and development expenses and therefore addresses research and development expenses for the three and six months ended June 30, 2025 and 2024.Read in the reply
Research and Development Expenses
We incur research and development expenses associated with bothRest of the answer
partnered and our own research activities, which we finance from our own cash-on-hand, financing arrangements with third parties, and reimbursement from our collaboration partners.
Research and development expenses for the three and six months ended
June 30, 2025 and 2024, were as follows (in thousands):
Three Months Ended
Six Months Ended
June 30,
2025
2024
Increase
External Costs:
Aficamten
$
29,390
20,958
8,432
58,938
44,155
14,783
Omecamtiv Mecarbil
3,967
954
3,013
7,564
6,680
884
Other programs
3,025
2,887
138
6,398
5,889
509
Unallocated
21,213
9,314
11,899
29,553
17,068
12,485
Total external costs
57,595
34,113
23,482
102,453
73,792
28,661
Internal Costs:
Employee related
41,109
32,634
8,475
81,136
63,934
17,202
Facilities, lab supplies and other
13,850
12,850
1,000
28,806
23,441
5,365
Total internal costs
54,959
45,484
9,475
109,942
87,375
22,567
Total research and development expense
112,554
79,597
32,957
212,395
161,167
51,228
Research and development expenses consist of external costs including contract research and manufacturing and consulting expenses. Aficamten external costs increased for the three and six months ended June 30, 2025, compared to the three and six months ended June 30, 2024, due primarily to the advancement of the ACACIA-HCM trial. Omecamtiv Mecarbil expenses increased in 2025 due to the COMET trial commencing in the fourth quarter of 2024. Unallocated external costs consist primarily of medical affairs, regulatory, quality and biostatistics.
We continue to develop aficamten to treat both oHCM and nHCM in three additional clinical trials, as follows: (i) MAPLE-HCM is our Phase 3 clinical trial of aficamten as a monotherapy for patients with oHCM, (ii) ACACIA-HCM is a Phase 3 clinical trial for patients with symptomatic nHCM, and (iii) CEDAR-HCM, our placebo-controlled and open-label extension clinical trial to evaluate the efficacy, pharmacokinetics (PK) and safety of aficamten in a pediatric population with symptomatic oHCM. Additionally, we have FOREST-HCM which is an open label extension study designed to assess the long term safety and tolerability of aficamten in patients with HCM.
We continue to develop omecamtiv mecarbil in COMET-HF, a Phase 3 clinical trial of omecamtiv mecarbil in patients with symptomatic HFrEF with severely reduced ejection fraction.
* * * * *
Please advise us if we can provide any further information or assistance to facilitate your review. Please direct any further comments or questions regarding this response letter to me at (949) 929-5744.
First report after the company's reply of Aug 8, 2025: 10-Q filed Nov 5, 2025 ↗, against the 10-Q filed May 6, 2025 ↗.
Tickdelta does not hold the text of both reports, so they are not compared here.
Also in this review: closing letter, 2025-08-13